A new prenatal cannabis exposure study used meconium testing and Medicaid claims to examine well-child visits, ED use, and developmental delay coding. The headline is simple: no signal of increased utilization burden, and no higher developmental delay by age 3 in this specific system and policy context. The harder lesson is about interpretation, because when policy triggers surveillance, outcomes can reflect systems as much as biology.